Menu
Oncology Evolved
with off-the-shelf cellular therapies for cancer
PIPELINE
PRE-CLINICAL
CLINICAL
AML
WU-NK-101
Head & Neck Cancer
WU-NK-101 + Cetuximab
Melanoma
WU-NK-101 (post-checkpoint inhibitor)
Solid Tumors
WU-NK-201
T-ALL
WU-CART-007
LATEST NEWS
Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials
Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B…
A fusion protein complex that combines IL12, IL15, and IL18 signaling to induce memory-like NK cells for cancer immunotherapy
Cancer Immunol Res, Becker-Hapak et al., July 2021
Cell-based immunotherapy shows promise against melanoma
Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.
Copyright © 2021 Wugen. All Rights Reserved.
a COGNEO design